| Institution | Role of Institution | Funding Institution | Reference | Designation | Principal Investigator |
|---|---|---|---|---|---|
|
International Projects |
|||||
| FFUL | Proponent | H2020-WIDESPREAD-2018-2020 / H2020-WIDESPREAD-2020-5 | GA 951996 | Straightening Training, Research and Innovation Capacities in the Valorization of Bio-Renewable Resources (Biomass4Synthons) | |
| FFUL | Proponent | Science for Peace and Security (SPS) NATO Program | SPS G5713 | Biofriendly Decontamination of Chemical Warfare Agents (EnzIL) | |
| FFUL | Proponent | European Society of Clinical Microbiology and Infectious Diseases (ESCMID) | ESCMID Research Grant 2018 | Decoding the peptidoglycan patterns associated with beta-lactams hypersusceptibility in drug-resistant Mycobacterium tuberculosis | |
| FFUL | Participant | Comissão Europeia | LIFE-Environment and Resource Efficiency | GA LIFE14 ENV/PT/000739 | Improving current barriers for controlling pharmaceutical compounds in urban wastewater treatment plants | |
| FFUL | Participant | Horizonte 2020 | Marie Sklodowska Curie Innovative Actions - Training Networks | H2020-MSCA-ITN-2016_GA_722619 | Bioenergetic remodelling in the pathophysiology and treatment of non-alcoholic fatty liver disease | |
| FFUL | Participant | Horizonte 2020 | Marie Sklodowska Curie Actions - Innovative Training Networks | MSCA-ITN-2015-ETN-675007 | A training network for the chemical site-selective modification of proteins: Preparation of the next-generation of therapeutic chemically-defined protein conjugates | |
| FFUL | Participant | Horizonte 2020 | Marie Sklodowska Curie Actions - Research and Innovation Staff Exchange | H2020-MSCA-RISE-2016_GA_ 734719 | Non-invasive Profiling of Mitochondrial Function in Non-Alcoholic Fatty Liver Disease | |
| FFUL | Participant | Horizonte 2020 | Innovative Medicines Initiative 2 | H2020-JTI-IMI2-2016-09-two-stage_GA_777377 | Identification and validation of biomarkers for non-alcoholic steatohepatitis (NASH) and across the spectrum of non-alcoholic fatty liver disease (NAFLD) | |